Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMF6V8W)

Drug Name
HALOPEMIDE Drug Info
Synonyms
Halopemide; 59831-65-1; UNII-65Q28TV0ZY; R 34,301; MLS003171133; 65Q28TV0ZY; CHEMBL245621; R-34301; N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide; Halopemida; Halopemidum; Halopemide [USAN:INN]; Halopemidum [INN-Latin]; Halopemida [INN-Spanish]; C21H22ClFN4O2; N-[2-[4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino]ethyl]-p-fluorobenzamide; Halopemide, 8; NSC 354856; Halopemide (USAN/INN); AC1L23CG; R 34301; MLS006012046; cid_65490; SCHEMBL121267; Halopemide, > CTK8G0128; AOB5520
Cross-matching ID
PubChem CID
65490
ChEBI ID
CHEMBL245621
CAS Number
CAS 59831-65-1
TTD Drug ID
D07RPV

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.13 0.00e+0 44/46 (95.65%) PSMF1;PSMD12;PSMA1;...
Ribosome -1.64 4.52e-2 113/158 (71.52%) RPL7;RPL18;MRPL11;...
Drug metabolism -1.66 3.91e-2 78/151 (51.66%) GSTA4;CDA;ADH7;...
Metabolism of xenobiotics by cytochrome P450 -1.67 3.71e-2 49/77 (63.64%) GSTM3;ADH1C;ADH5;...
Amoebiasis -1.69 3.22e-2 99/102 (97.06%) PLCB3;COL4A6;NFKB1;...
Protein processing in endoplasmic reticulum -1.72 2.40e-2 127/171 (74.27%) RPN1;BCAP31;SEC61A1;...
Tryptophan metabolism -1.74 1.70e-2 35/42 (83.33%) AOX1;KYAT1;ACAT2;...
Mineral absorption -1.75 1.83e-2 48/60 (80%) SLC39A4;ATP1B1;SLC34A2;...
Rheumatoid arthritis -1.78 1.30e-2 78/93 (83.87%) ATP6V1E1;ATP6V0E2;TLR4;...
Histidine metabolism -1.79 1.04e-2 16/22 (72.73%) CNDP2;ASPA;MAOA;...
Fatty acid degradation -1.84 5.73e-3 40/43 (93.02%) ACADVL;ADH1C;ECI2;...
Mucin type O-glycan biosynthesis -1.87 3.64e-3 20/36 (55.56%) B4GALT5;ST3GAL1;GALNT3;...
Legionellosis -1.88 3.07e-3 51/57 (89.47%) BNIP3;NFKB1;HSPA6;...
African trypanosomiasis -1.91 0.00e+0 32/37 (86.49%) IFNG;PLCB3;FAS;...
TNF signaling pathway -1.92 0.00e+0 103/112 (91.96%) MAP3K7;IRF1;BAG4;...
Coronavirus disease -1.92 0.00e+0 215/232 (92.67%) RPS3A;IFNA17;MAS1;...
NF-kappa B signaling pathway -1.98 0.00e+0 90/104 (86.54%) NFKB1;TLR4;PRKCB;...
Sulfur metabolism -2.00 0.00e+0 9/10 (90%) ETHE1;MPST;SQOR;...
IL-17 signaling pathway -2.08 0.00e+0 84/94 (89.36%) JUN;NFKBIA;HSP90AA1;...
Viral protein interaction with cytokine and cytokine re... -2.12 0.00e+0 84/100 (84%) IL6;IL10RB;CCL21;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 3.33uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H